An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. / Jørgensen, Peter G.; Schou, Morten; Biering-Sørensen, Tor; Mogelvang, Rasmus; Fritz-Hansen, Thomas; Vilsbøll, Tina; Rossing, Peter; Jensen, Magnus T.

In: International Journal of Cardiology, Vol. 289, 2019, p. 119-124.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Jørgensen, PG, Schou, M, Biering-Sørensen, T, Mogelvang, R, Fritz-Hansen, T, Vilsbøll, T, Rossing, P & Jensen, MT 2019, 'An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes', International Journal of Cardiology, vol. 289, pp. 119-124. https://doi.org/10.1016/j.ijcard.2019.04.093

APA

Jørgensen, P. G., Schou, M., Biering-Sørensen, T., Mogelvang, R., Fritz-Hansen, T., Vilsbøll, T., Rossing, P., & Jensen, M. T. (2019). An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. International Journal of Cardiology, 289, 119-124. https://doi.org/10.1016/j.ijcard.2019.04.093

Vancouver

Jørgensen PG, Schou M, Biering-Sørensen T, Mogelvang R, Fritz-Hansen T, Vilsbøll T et al. An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. International Journal of Cardiology. 2019;289:119-124. https://doi.org/10.1016/j.ijcard.2019.04.093

Author

Jørgensen, Peter G. ; Schou, Morten ; Biering-Sørensen, Tor ; Mogelvang, Rasmus ; Fritz-Hansen, Thomas ; Vilsbøll, Tina ; Rossing, Peter ; Jensen, Magnus T. / An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. In: International Journal of Cardiology. 2019 ; Vol. 289. pp. 119-124.

Bibtex

@article{e9adf87446f1430aaced982d2a8fd5b4,
title = "An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes",
abstract = "Background: Dyspnea is a common clinical challenge in patients with type 2 diabetes and may be a sign of heart failure (HF). We sought to evaluate the predictive value dyspnea with and without an echocardiographic substrate in patients with type 2 diabetes without known heart disease. Methods: A total of 724 patients with type 2 diabetes followed at specialized clinics participated in this prospective cohort study. Clinical evaluation, comprehensive echocardiography and follow-up through national registers were performed. An echocardiographic substrate was either left ventricular hypertrophy, increased left atrial size, E/e{\textquoteright} > 15, or LV ejection fraction<50%. The end-points were cardiovascular (CVD)events and all-cause mortality. Results: Median follow-up was 4.8 years [Interquartile range: 4.1, 5.3]for CVD event and 77 patients suffered a CVD event. Dyspnea was significantly associated with CVD event: Hazard ratio (HR): 1.58 (95% confidence interval: 1.01–2.48), p = 0.04. Stratifying by evidence of echocardiographic substrate revealed high risk individuals: CVD event: 0.71 (0.35–1.46), p = NS in patients with dyspnea and no echocardiographic substrate and 2.85 (1.74–4.67), p < 0.001 in patients with dyspnea with echocardiographic substrate). This pattern was similar in multivariable analyses. Also, C-statistics improved from 0.66 (0.60–0.72)to 0.69 (0.63–0.75), p < 0.001 and net reclassification index was 27.5%(5.0–50.0), p = 0.01 for CVD event. The results were similar for all-cause mortality except dyspnea was only a borderline significant predictor. Conclusion: In patients with type 2 diabetes complaining of dyspnea, identifying an echocardiographic substrate - thus indicating patients with HF - accurately stratifies patients with increased risk of CV events and all-cause mortality.",
keywords = "Echocardiography, Heart failure with preserved ejection fraction, Type 2 diabetes",
author = "J{\o}rgensen, {Peter G.} and Morten Schou and Tor Biering-S{\o}rensen and Rasmus Mogelvang and Thomas Fritz-Hansen and Tina Vilsb{\o}ll and Peter Rossing and Jensen, {Magnus T.}",
year = "2019",
doi = "10.1016/j.ijcard.2019.04.093",
language = "English",
volume = "289",
pages = "119--124",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes

AU - Jørgensen, Peter G.

AU - Schou, Morten

AU - Biering-Sørensen, Tor

AU - Mogelvang, Rasmus

AU - Fritz-Hansen, Thomas

AU - Vilsbøll, Tina

AU - Rossing, Peter

AU - Jensen, Magnus T.

PY - 2019

Y1 - 2019

N2 - Background: Dyspnea is a common clinical challenge in patients with type 2 diabetes and may be a sign of heart failure (HF). We sought to evaluate the predictive value dyspnea with and without an echocardiographic substrate in patients with type 2 diabetes without known heart disease. Methods: A total of 724 patients with type 2 diabetes followed at specialized clinics participated in this prospective cohort study. Clinical evaluation, comprehensive echocardiography and follow-up through national registers were performed. An echocardiographic substrate was either left ventricular hypertrophy, increased left atrial size, E/e’ > 15, or LV ejection fraction<50%. The end-points were cardiovascular (CVD)events and all-cause mortality. Results: Median follow-up was 4.8 years [Interquartile range: 4.1, 5.3]for CVD event and 77 patients suffered a CVD event. Dyspnea was significantly associated with CVD event: Hazard ratio (HR): 1.58 (95% confidence interval: 1.01–2.48), p = 0.04. Stratifying by evidence of echocardiographic substrate revealed high risk individuals: CVD event: 0.71 (0.35–1.46), p = NS in patients with dyspnea and no echocardiographic substrate and 2.85 (1.74–4.67), p < 0.001 in patients with dyspnea with echocardiographic substrate). This pattern was similar in multivariable analyses. Also, C-statistics improved from 0.66 (0.60–0.72)to 0.69 (0.63–0.75), p < 0.001 and net reclassification index was 27.5%(5.0–50.0), p = 0.01 for CVD event. The results were similar for all-cause mortality except dyspnea was only a borderline significant predictor. Conclusion: In patients with type 2 diabetes complaining of dyspnea, identifying an echocardiographic substrate - thus indicating patients with HF - accurately stratifies patients with increased risk of CV events and all-cause mortality.

AB - Background: Dyspnea is a common clinical challenge in patients with type 2 diabetes and may be a sign of heart failure (HF). We sought to evaluate the predictive value dyspnea with and without an echocardiographic substrate in patients with type 2 diabetes without known heart disease. Methods: A total of 724 patients with type 2 diabetes followed at specialized clinics participated in this prospective cohort study. Clinical evaluation, comprehensive echocardiography and follow-up through national registers were performed. An echocardiographic substrate was either left ventricular hypertrophy, increased left atrial size, E/e’ > 15, or LV ejection fraction<50%. The end-points were cardiovascular (CVD)events and all-cause mortality. Results: Median follow-up was 4.8 years [Interquartile range: 4.1, 5.3]for CVD event and 77 patients suffered a CVD event. Dyspnea was significantly associated with CVD event: Hazard ratio (HR): 1.58 (95% confidence interval: 1.01–2.48), p = 0.04. Stratifying by evidence of echocardiographic substrate revealed high risk individuals: CVD event: 0.71 (0.35–1.46), p = NS in patients with dyspnea and no echocardiographic substrate and 2.85 (1.74–4.67), p < 0.001 in patients with dyspnea with echocardiographic substrate). This pattern was similar in multivariable analyses. Also, C-statistics improved from 0.66 (0.60–0.72)to 0.69 (0.63–0.75), p < 0.001 and net reclassification index was 27.5%(5.0–50.0), p = 0.01 for CVD event. The results were similar for all-cause mortality except dyspnea was only a borderline significant predictor. Conclusion: In patients with type 2 diabetes complaining of dyspnea, identifying an echocardiographic substrate - thus indicating patients with HF - accurately stratifies patients with increased risk of CV events and all-cause mortality.

KW - Echocardiography

KW - Heart failure with preserved ejection fraction

KW - Type 2 diabetes

U2 - 10.1016/j.ijcard.2019.04.093

DO - 10.1016/j.ijcard.2019.04.093

M3 - Journal article

C2 - 31078354

AN - SCOPUS:85065172182

VL - 289

SP - 119

EP - 124

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -

ID: 230200251